SAM
ENTA icon

Shell Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Shell Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,784
Closed -$53K – 1259
2023
Q3 		$53K Sell
4,784
-75
-2% -$1.21K ﹤0.01% 1181
2023
Q2 		$104K Sell
4,859
-28
-0.6% -$825 ﹤0.01% 1111
2023
Q1 		$198K Sell
4,887
-17
-0.3% -$812 0.01% 926
2022
Q4 		$228K Sell
4,904
-1,035
-17% -$47.2K 0.01% 903
2022
Q3 		$308K Sell
5,939
-1,547
-21% -$90.4K 0.01% 815
2022
Q2 		$354K Buy
7,486
+17
+0.2% +$923 0.01% 894
2022
Q1 		$532K Sell
7,469
-1,104
-13% -$71.8K 0.01% 786
2021
Q4 		$641K Buy
8,573
+29
+0.3% +$2.28K 0.01% 782
2021
Q3 		$485K Sell
8,544
-370
-4% -$18.3K 0.01% 881
2021
Q2 		$392K Buy
8,914
+480
+6% +$23.5K 0.01% 1017
2021
Q1 		$416K Buy
8,434
+4,368
+107% +$218K 0.01% 924
2020
Q4 		$171K Hold
4,066
– – ﹤0.01% 1162
2020
Q3 		$186K Buy
4,066
+825
+25% +$40K ﹤0.01% 1060
2020
Q2 		$163K Buy
3,241
+9
+0.3% +$466 ﹤0.01% 1064
2020
Q1 		$166K Sell
3,232
-50
-2% -$2.67K ﹤0.01% 1047
2019
Q4 		$203K Sell
3,282
-123
-4% -$7.63K ﹤0.01% 1129
2019
Q3 		$205K Sell
3,405
-29
-0.8% -$2.15K ﹤0.01% 1127
2019
Q2 		$290K Sell
3,434
-2,631
-43% -$237K 0.01% 1060
2019
Q1 		$579K Hold
6,065
– – 0.01% 844
2018
Q4 		$430K Sell
6,065
-500
-8% -$38.3K 0.01% 888
2018
Q3 		$561K Buy
+6,565
New +$658K 0.01% 921
2017
Q1 		– Sell
-15,946
Closed -$497K – 1090
2016
Q4 		$534K Buy
+15,946
New +$457K 0.01% 858

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Shell Asset Management's ENTA Position: Q4 2023 in Review

Shell Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 4,784 shares — an estimated $53K sold.

Shell Asset Management first reported a position in ENTA in Q4 2016 and held it in 22 quarters. The position peaked at $641K in Q4 2021. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Shell Asset Management reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Shell Asset Management sold 4,784 Enanta Pharmaceuticals shares in Q4 2023, an estimated $53K.
  • Shell Asset Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 22 quarters.
  • Shell Asset Management's Enanta Pharmaceuticals position peaked at $641K in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Shell Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.